Back to News & Events

Rgenix Announces $33M Series B Financing

regenix_web1Rgenix, a cancer therapeutics company developing first-in-class drugs targeting novel cancer pathways, announced a $33 million Series B financing led by Novo A/S and Sofinnova Partners, with participation from existing investors including Partnership Fund for New York City, Alexandria Venture Investments, and Conegliano Ventures LP. The financing will support clinical development of Rgenix’s lead drug candidates, RGX-104 and RGX-202, as well as further development of its therapeutics pipeline.

In connection with the financing, Nilesh Kumar of Novo Ventures and Antoine Papiernik of Sofinnova Partners will join the Rgenix Board of Directors together with existing members, including Executive Chairman Eric Rowinsky, M.D., Masoud Tavazoie, M.D. Ph.D., Nancy Chang, Ph.D., and Saeed Tavazoie, Ph.D. Read the full press release about Rgenix’s financing here.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4439
                    [post_author] => 3
                    [post_date] => 2024-07-30 15:29:07
                    [post_date_gmt] => 2024-07-30 19:29:07
                    [post_content] => 

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-08-09 15:38:43 [post_modified_gmt] => 2024-08-09 19:38:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 3290 [post_author] => 3 [post_date] => 2019-07-18 19:14:24 [post_date_gmt] => 2019-07-18 19:14:24 [post_content] => Phase 0 Proof-of-Concept Partnership pilot program demonstrates effectiveness for transitioning basic science discoveries into the commercialization pipeline. The Long Island Bioscience Hub (LIBH), a National Institutes of Health (NIH) Research Evaluation and Commercialization Hub (REACH), is pleased to announce it has demonstrated significant impact as outlined in a recent evaluative report presenting the results and activities of the NIH REACH program over the pilot period of three years. The LIBH, a collaboration between Stony Brook University, Brookhaven National Laboratory, Cold Spring Harbor Laboratory, and the Feinstein Institute at Northwell Health, led by the Center for Biotechnology, was formed in March 2015 with a mission to help commercialize biomedical technologies emerging from the region’s research institutions. The report, prepared independently by RTI International on behalf of the NIH, outlines multiple outcomes from the REACH program, and documents the successes that the LIBH has had during the relatively short pilot phase of its work. The LIBH engaged 600 innovators in training sponsored or co-sponsored by the REACH Program. Fifty technology development projects have been funded by LIBH over the course of three years, including technologies focused on biologic drugs, diagnostic devices, small molecule drugs, therapeutic devices, and Health IT among others. As a result of the NIH investment in the LIBH, ten startup companies have been formed and two license agreements have been executed. In addition, the initial investment made by NIH in the region has generated follow on funding of more than $10 million, $2.8 million coming from five funded SBIR/STTR proposals based on LIBH technologies. This impact from the REACH program contributes to the overall economic impact of Center for Biotechnology, notably $1.2B over a recent fifteen year period. “We are thrilled with the outcomes reported in the RTI evaluation for the Long Island Bioscience Hub’s efforts thus far under the REACH program” said Clinton T. Rubin, Ph.D., Distinguished Professor, Department of Biomedical Engineering, and Director, Center for Biotechnology. “Through the REACH program we’ve been able to expand on the region’s efforts to commercialize more innovation locally, thereby capturing more of the economic impact within the region. While the pilot program will end in mid-2019, these impacts clearly demonstrate the potential of the model to make significant contributions to our innovation ecosystem.” “The RTI evaluation reinforces our knowledge that the Long Island Bioscience Hub model has already had a significant, positive impact on technologies and innovators embedded in our research community” stated Dr. Richard Reeder, Vice President for Research at Stony Brook University. “It is imperative we continue to fuel the activities of the LIBH as it is an essential part of innovation economy, and is a significant engine in bringing lifesaving technologies to patients.” The Center for Biotechnology, in collaboration with other partners in the region, will continue to explore how the model might be continued and expanded. Click here for PDF version. [post_title] => Long Island Bioscience Hub Reports Significant Impacts [post_excerpt] => The Long Island Bioscience Hub, is pleased to announce it has demonstrated significant impact as outlined in a recent evaluative report presenting the results and activities of the NIH REACH program over the pilot period of three years. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => news-libh-impacts [to_ping] => [pinged] => https://centerforbiotechnology.org/who-we-are/long-island-bioscience-hub/ [post_modified] => 2019-07-18 19:15:46 [post_modified_gmt] => 2019-07-18 19:15:46 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3290 [menu_order] => 93 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 2689 [post_author] => 3 [post_date] => 2017-05-08 17:15:49 [post_date_gmt] => 2017-05-08 17:15:49 [post_content] => The Center for Biotechnology (CFB) at Stony Brook University is a New York State Center for Advanced Technology and the lead institution of the Long Island Bioscience Hub. The CFB provides the cross-institutional infrastructure for technology development, technology transfer, strategic industry partnerships, new company formation, attraction of investment capital, and other commercialization activities. The CFB seeks ongoing technology and business development consulting services for its faculty and small business clients. The CFB works primarily with faculty and emerging small businesses to help them develop their technology and business strategy to prepare them for strategic partnerships and/or investment. Consulting services anticipated, but not limited to:
  • Conduct thorough due diligence on select technologies under consideration for investment by the CFB. Develop written assessments.
  • Participate in in-person meetings on a weekly basis with faculty innovators and emerging companies to provide strategic guidance in intellectual property, competitive analysis, regulatory strategy, manufacturing, company formation and other issues related to commercialization strategies.
  • Actively manage a project portfolio of funded technologies ensuring milestones are met and will add commercial value.
  • Assist faculty in the development of applications for funding.
  • Assist clients to develop effective fundraising strategies and materials.
  • Participate in CFB technology and business development initiatives including the Boot Camp, Strategy Sessions, Long Island BioMentor Service and Life Sciences Summit.
  • Help source and conduct due diligence on emerging company candidates for the Life Sciences Summit.
  • Consult with CFB on specific technologies regarding commercialization and viability for moving forward.
  • Consult with CFB clients on milestones required for licensing, strategic partnerships, investment, and/or manufacturing.
  • Consult with CFB staff on client work, intellectual property, as well as patent, regulatory, commercialization strategies as needed.
  • Consult on course content for CFB programs such as the Innovation Boot Camp and Fundamentals course. Serve as instructor or guest lecturer as needed.
  • Review, interpretation, and advice of patents, websites, articles related to specific technology. Required Qualifications:
  • Direct experience in the management of business and technical issues associated with advanced bio-based technology commercialization, including:
    •  Due Diligence
    •  IP Strategy
    •  Fundraising
    • Product development
    •  Regulatory
    • Manufacturing (preferred)
    • Sales and Marketing (preferred)
    •  Licensing
  • Technology development experience in working with faculty-members and entrepreneurs seeking to commercialize early-stage technologies.
  • Experience in technology development and initial IP landscape review and strategy development.
  • Experience in the grant application review and the management of approved grants, including the identification and achievement of milestones that have material commercial value.
Progress Reports Progress reports detailing meetings held/attended, project development issues, priorities, and other issues of importance are required on a monthly basis. Time Commitment
  • No less than one full day per week.
  • Must be available to meet onsite and in-person with CFB staff and clients as needed and required by the CFB.
  • Ability to respond to urgent requests and to fill in as needed is desirable.
Proposal Deadline The CFB seeks proposals from qualified providers who have the expertise and desire to support the technology and business development objectives of the CFB. Interested parties should submit a proposal of no more than one page to Kristina Duryea at Kristina.Duryea@stonybrook.edu by 5p, May 26, 2017. [post_title] => Request for Proposals: Technology & Business Development Services [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => request-for-proposals-technology-business-development-services [to_ping] => [pinged] => [post_modified] => 2017-05-08 17:15:49 [post_modified_gmt] => 2017-05-08 17:15:49 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2689 [menu_order] => 147 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 3912 [post_author] => 3 [post_date] => 2022-08-22 13:06:25 [post_date_gmt] => 2022-08-22 13:06:25 [post_content] =>

November 2-3, 2022 | Virtual

The Life Sciences Summit is an exclusive early stage investor and business development conference that highlights innovation. The objective of the event is to provide an intimate setting allowing emerging biotech companies and academic innovators to connect with the capital and strategic partners they will need to move new discoveries through clinical development.

The virtual 2022 program features thought provoking plenary sessions, presentations by promising young companies with transformative science, the "innovation pipeline" featuring academic innovators and pre-seed stage companies working on cutting edge technologies, and 1:1 networking opportunities.

View full details onlifesciencessummit.org

[post_title] => Save the Date! LSS 2022 [post_excerpt] => Join the Center for Biotechnology November 2-3 at our Virtual Life Sciences Summit 2022! [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => save-the-date-lss-2022 [to_ping] => [pinged] => [post_modified] => 2022-12-13 17:04:15 [post_modified_gmt] => 2022-12-13 17:04:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3912 [menu_order] => 23 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4439 [post_author] => 3 [post_date] => 2024-07-30 15:29:07 [post_date_gmt] => 2024-07-30 19:29:07 [post_content] =>

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-08-09 15:38:43 [post_modified_gmt] => 2024-08-09 19:38:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 260 [max_num_pages] => 87 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

IAMBIC Receives $1 Million NSF SBIR Phase II Grant

More Information

Long Island Bioscience Hub Reports Significant Impacts

More Information

Request for Proposals: Technology & Business Development Services

More Information

Save the Date! LSS 2022

More Information